358 related articles for article (PubMed ID: 35873144)
1. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
Song X; Han M
Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
[TBL] [Abstract][Full Text] [Related]
2. Competence Mining of Vancomycin (VAN) in the Management of Infections Due to Bacterial Strains With High VAN Minimum Inhibitory Concentrations (MICs): A Novel Dosing Strategy Based on Pharmacokinetic/Pharmacodynamic Modeling.
Song X; Zeng M; Wu Y; Pan Y
Front Microbiol; 2021; 12():649757. PubMed ID: 33967986
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
4. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.
Revilla N; Martín-Suárez A; Pérez MP; González FM; Fernández de Gatta Mdel M
Br J Clin Pharmacol; 2010 Aug; 70(2):201-12. PubMed ID: 20653673
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Intermittent Vancomycin Dosage Regimens for Thai Critically Ill Population Infected by MRSA in the Era of the "MIC Creep" Phenomenon.
Setiawan E; Suwannoi L; Montakantikul P; Chindavijak B
Acta Med Indones; 2019 Jan; 51(1):10-18. PubMed ID: 31073101
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis.
Yellepeddi VK; Lindley B; Radetich E; Kumar S; Bhakta Z; Leclair L; Parrot M; Young DC
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0099223. PubMed ID: 38059634
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin: we can't get there from here.
Patel N; Pai MP; Rodvold KA; Lomaestro B; Drusano GL; Lodise TP
Clin Infect Dis; 2011 Apr; 52(8):969-74. PubMed ID: 21460308
[TBL] [Abstract][Full Text] [Related]
8. Sequence Type 5 (ST5) as a Possible Predictor of Bacterial Persistence in Adult Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia Treated with Vancomycin.
Fan YX; Chen MT; Li NY; Liu XF; Yang MJ; Chen YC; Liang XY; Wu JF; Guo BN; Song SC; Zhu YQ; Zhang FY; Hang JQ; Wu SB; Shen B; Li HY; Wang Q; Luo XM; Chen QG; Zhang HF; Wang RL; Shen LH; Fu FM; Song XL; Zhang J
Microbiol Spectr; 2022 Oct; 10(5):e0134822. PubMed ID: 36094217
[TBL] [Abstract][Full Text] [Related]
9. Initial dosage regimen of vancomycin for septic shock patients: a pharmacokinetic study and Monte Carlo simulation.
Katip Bpharm W; Jaruratanasirikul S; Pattharachayakul S; Wongpoowarak W; Jitsurong A
J Med Assoc Thai; 2014 Nov; 97(11):1209-19. PubMed ID: 25675687
[TBL] [Abstract][Full Text] [Related]
10. Optimal vancomycin dosing regimens for critically ill patients with acute kidney injury during continuous renal replacement therapy: A Monte Carlo simulation study.
Charoensareerat T; Chaijamorn W; Boonpeng A; Srisawat N; Pummangura C; Pattharachayakul S
J Crit Care; 2019 Dec; 54():77-82. PubMed ID: 31394493
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
[No Abstract] [Full Text] [Related]
12. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
Nicasio AM; Bulitta JB; Lodise TP; D'Hondt RE; Kulawy R; Louie A; Drusano GL
Antimicrob Agents Chemother; 2012 Feb; 56(2):682-6. PubMed ID: 22083484
[TBL] [Abstract][Full Text] [Related]
13. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.
Giuliano C; Haase KK; Hall R
Expert Rev Anti Infect Ther; 2010 Jan; 8(1):95-106. PubMed ID: 20014904
[TBL] [Abstract][Full Text] [Related]
14. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
[TBL] [Abstract][Full Text] [Related]
15. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
16. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.
Frymoyer A; Hersh AL; Benet LZ; Guglielmo BJ
Pediatr Infect Dis J; 2009 May; 28(5):398-402. PubMed ID: 19295465
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of individualised patient modelling for continuous vancomycin infusions in outpatient antimicrobial therapy, a retrospective study.
Nolan J; McCarthy K; Farkas A; Avent ML
Int J Clin Pharm; 2023 Dec; 45(6):1444-1451. PubMed ID: 37532840
[TBL] [Abstract][Full Text] [Related]
18. Prospective Cohort Study of Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Adults on Extracorporeal Membrane Oxygenation.
Jung Y; Lee DH; Kim HS
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33257444
[TBL] [Abstract][Full Text] [Related]
19. Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients.
Gonzalez N; Sevillano D; Alou L; Cafini F; Gimenez MJ; Gomez-Lus ML; Prieto J; Aguilar L
J Antimicrob Chemother; 2013 Oct; 68(10):2291-5. PubMed ID: 23674766
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
